首页 > 最新文献

Journal of medical microbiology最新文献

英文 中文
The effect of daily usage of Listerine Cool Mint mouthwash on the oropharyngeal microbiome: a substudy of the PReGo trial. 每天使用李施德林薄荷漱口水对口咽微生物组的影响:PReGo 试验的子研究。
Pub Date : 2024-06-01 DOI: 10.1099/jmm.0.001830
J G E Laumen, C Van Dijck, S S Manoharan-Basil, T de Block, S Abdellati, B B Xavier, S Malhotra-Kumar, C Kenyon

Introduction. ListerineÒ is a bactericidal mouthwash widely used to prevent oral health problems such as dental plaque and gingivitis. However, whether it promotes or undermines a healthy oral microbiome is unclear.Hypothesis/Gap Statement. We hypothesized that the daily use of Listerine Cool Mint would have a significant impact on the oropharyngeal microbiome.Aim. We aimed to assess if daily usage of Listerine Cool Mint influenced the composition of the pharyngeal microbiome.Methodology. The current microbiome substudy is part of the Preventing Resistance in Gonorrhoea trial. This was a double-blind single-centre, crossover, randomized controlled trial of antibacterial versus placebo mouthwash to reduce the incidence of gonorrhoea/chlamydia/syphilis in men who have sex with men (MSM) taking HIV pre-exposure prophylaxis (PrEP). Fifty-nine MSM taking HIV PrEP were enrolled. In this crossover trial, participants received 3 months of daily Listerine followed by 3 months of placebo mouthwash or vice versa. Oropharyngeal swabs were taken at baseline and after 3 months use of each mouthwash. DNA was extracted for shotgun metagenomic sequencing (Illumina Inc.). Non-host reads were taxonomically classified with MiniKraken and Bracken. The alpha and beta diversity indices were compared between baseline and after each mouthwash use. Differentially abundant bacterial taxa were identified using ANOVA-like differential expression analysis.Results. Streptococcus was the most abundant genus in most samples (n = 103, 61.7 %) with a median relative abundance of 31.5% (IQR 20.6-44.8), followed by Prevotella [13.5% (IQR 4.8-22.6)] and Veillonella [10.0% (IQR 4.0-16.8)]. Compared to baseline, the composition of the oral microbiome at the genus level (beta diversity) was significantly different after 3 months of Listerine (P = 0.006, pseudo-F = 2.29) or placebo (P = 0.003, pseudo-F = 2.49, permutational multivariate analysis of variance) use. Fusobacterium nucleatum and Streptococcus anginosus were significantly more abundant after Listerine use compared to baseline.Conclusion. Listerine use was associated with an increased abundance of common oral opportunistic bacteria previously reported to be enriched in periodontal diseases, oesophageal and colorectal cancer, and systemic diseases. These findings suggest that the regular use of Listerine mouthwash should be carefully considered.

简介李施德林Ò是一种杀菌漱口水,被广泛用于预防牙菌斑和牙龈炎等口腔健康问题。然而,它是促进还是破坏健康的口腔微生物群还不清楚。我们假设每天使用李施德林清凉薄荷漱口水会对口咽微生物群产生重大影响。我们旨在评估每天使用李施德林清凉薄荷是否会影响咽部微生物组的组成。目前的微生物组子研究是预防淋病耐药性试验的一部分。这是一项双盲、单中心、交叉、随机对照试验,目的是通过抗菌漱口水与安慰剂的对比,降低服用艾滋病暴露前预防药物(PrEP)的男男性行为者(MSM)的淋病/衣原体/梅毒发病率。59 名男男性行为者正在服用 HIV PrEP。在这项交叉试验中,参与者每天使用李施德林漱口水 3 个月,然后再使用安慰剂漱口水 3 个月,反之亦然。在基线和使用每种漱口水 3 个月后,分别采集口咽拭子。提取 DNA 进行射枪元基因组测序(Illumina 公司)。用 MiniKraken 和 Bracken 对非宿主读数进行分类。比较了基线和每次使用漱口水后的α和β多样性指数。使用类似方差分析的差异表达分析确定了差异丰富的细菌类群。链球菌是大多数样本中含量最高的菌属(n = 103,61.7%),相对含量中位数为 31.5%(IQR 20.6-44.8),其次是普雷沃特氏菌[13.5%(IQR 4.8-22.6)]和维氏菌[10.0%(IQR 4.0-16.8)]。与基线相比,使用李施德林(P = 0.006,pseudo-F = 2.29)或安慰剂(P = 0.003,pseudo-F = 2.49, permutational multivariate analysis of variance)3 个月后,口腔微生物群的属级组成(β 多样性)有显著差异。与基线相比,使用李施德林后核分枝杆菌和副猪链球菌的数量明显增加。使用李施德林与常见口腔机会性细菌数量的增加有关,此前曾有报道称这些细菌在牙周病、食道癌、结肠直肠癌和全身性疾病中富集。这些研究结果表明,应谨慎考虑定期使用李施德林漱口水。
{"title":"The effect of daily usage of Listerine Cool Mint mouthwash on the oropharyngeal microbiome: a substudy of the PReGo trial.","authors":"J G E Laumen, C Van Dijck, S S Manoharan-Basil, T de Block, S Abdellati, B B Xavier, S Malhotra-Kumar, C Kenyon","doi":"10.1099/jmm.0.001830","DOIUrl":"10.1099/jmm.0.001830","url":null,"abstract":"<p><p><b>Introduction.</b> Listerine<sup>Ò</sup> is a bactericidal mouthwash widely used to prevent oral health problems such as dental plaque and gingivitis. However, whether it promotes or undermines a healthy oral microbiome is unclear.<b>Hypothesis/Gap Statement.</b> We hypothesized that the daily use of Listerine Cool Mint would have a significant impact on the oropharyngeal microbiome.<b>Aim.</b> We aimed to assess if daily usage of Listerine Cool Mint influenced the composition of the pharyngeal microbiome.<b>Methodology.</b> The current microbiome substudy is part of the Preventing Resistance in Gonorrhoea trial. This was a double-blind single-centre, crossover, randomized controlled trial of antibacterial versus placebo mouthwash to reduce the incidence of gonorrhoea/chlamydia/syphilis in men who have sex with men (MSM) taking HIV pre-exposure prophylaxis (PrEP). Fifty-nine MSM taking HIV PrEP were enrolled. In this crossover trial, participants received 3 months of daily Listerine followed by 3 months of placebo mouthwash or vice versa. Oropharyngeal swabs were taken at baseline and after 3 months use of each mouthwash. DNA was extracted for shotgun metagenomic sequencing (Illumina Inc.). Non-host reads were taxonomically classified with MiniKraken and Bracken. The alpha and beta diversity indices were compared between baseline and after each mouthwash use. Differentially abundant bacterial taxa were identified using ANOVA-like differential expression analysis.<b>Results.</b> <i>Streptococcus</i> was the most abundant genus in most samples (<i>n</i> = 103, 61.7 %) with a median relative abundance of 31.5% (IQR 20.6-44.8), followed by <i>Prevotella</i> [13.5% (IQR 4.8-22.6)] and <i>Veillonella</i> [10.0% (IQR 4.0-16.8)]. Compared to baseline, the composition of the oral microbiome at the genus level (beta diversity) was significantly different after 3 months of Listerine (<i>P</i> = 0.006, pseudo-<i>F</i> = 2.29) or placebo (<i>P</i> = 0.003, pseudo-<i>F</i> = 2.49, permutational multivariate analysis of variance) use. <i>Fusobacterium nucleatum</i> and <i>Streptococcus anginosus</i> were significantly more abundant after Listerine use compared to baseline.<b>Conclusion.</b> Listerine use was associated with an increased abundance of common oral opportunistic bacteria previously reported to be enriched in periodontal diseases, oesophageal and colorectal cancer, and systemic diseases. These findings suggest that the regular use of Listerine mouthwash should be carefully considered.</p>","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ciprofloxacin prophylaxis during haematopoietic cell transplantation: a role for use in patients with germ cell tumours? 造血细胞移植期间的环丙沙星预防措施:生殖细胞肿瘤患者的使用作用?
Pub Date : 2024-06-01 DOI: 10.1099/jmm.0.001847
Konstantinos Kavallieros, Ioannis Baltas, Giannis Konstantinou, Eirini Koutoumanou, Malick M Gibani, Mark Gilchrist, Frances Davies, Jiri Pavlu

Introduction. Fluoroquinolone prophylaxis during haematopoietic cell transplantation (HCT) can lead to antimicrobial resistance (AMR). Identifying the groups of patients that have the highest likelihood of benefiting from prophylactic antimicrobials is important for antimicrobial stewardship (AMS).Hypothesis. We aimed to identify groups of HCT recipients that have the highest likelihood of benefiting from prophylactic fluroquinolones.Methods. All admissions for HCT in a tertiary centre between January 2020 and December 2022 (N = 400) were retrospectively studied. Allogeneic HCT (allo-HCT) recipients had prophylaxis with ciprofloxacin during the chemotherapy-induced neutropenia, while autologous HCT (auto-HCT) recipients did not. Bacteraemias were recorded when non-contaminant bacterial pathogens were isolated in blood cultures.Results. Allo-HCT was performed for 43.3 % (173/400) of patients and auto-HCT was performed for 56.7 % (227/400). A bacteraemia was documented in 28.3 % (113/400) of cases. Allo-HCT recipients were more likely to have a Gram-positive bacteraemia (20.8%, 36/173, vs 10.1%, 23/227, P = 0.03), while a difference was not observed for Gram-negative bacteraemias (18.5%, 32/173 vs 18.1%, 41/227, P = 0.91). Among auto-HCT recipients not receiving ciprofloxacin prophylaxis, patients with germ cell tumours had the highest probability (P for trend 0.09) of recording any bacteraemia (43.5%, 10/23) followed by patients with lymphomas (32.5%, 13/40), other auto-HCT indications (22.2%, 2/9), multiple myeloma (22.1%, 29/131) and multiple sclerosis (12.5%, 3/24). The higher number of bacteraemias in patients with germ cell tumours was primarily driven by Gram-negative pathogens.Conclusions. Ciprofloxacin prophylaxis was associated with a reduced incidence of Gram-negative bacteraemias in allo-HCT recipients. Auto-HCT recipients due to germ cell tumours, not receiving ciprofloxacin prophylaxis, recorded the highest incidence of bacteraemias and represent a possible target group for this intervention.

简介。在造血细胞移植(HCT)过程中使用氟喹诺酮类药物进行预防可能会导致抗菌药耐药性(AMR)。确定最有可能从预防性抗菌药物中获益的患者群体对于抗菌药物管理(AMS)非常重要。我们的目的是找出最有可能从预防性氟喹诺酮类药物中获益的造血干细胞移植受者群体。我们对一家三级医疗中心在2020年1月至2022年12月期间收治的所有HCT患者(N = 400)进行了回顾性研究。异体造血干细胞移植(allo-HCT)受者在化疗引起的中性粒细胞减少症期间使用环丙沙星预防,而自体造血干细胞移植(auto-HCT)受者则不使用环丙沙星。如果血液培养中分离出非污染性细菌病原体,则记录为菌血症。43.3%的患者(173/400)接受了异体 HCT,56.7%的患者(227/400)接受了自体 HCT。28.3%的病例(113/400)发生了菌血症。接受自身血液透析的患者更有可能发生革兰氏阳性菌血症(20.8%,36/173 对 10.1%,23/227,P = 0.03),而革兰氏阴性菌血症则无差异(18.5%,32/173 对 18.1%,41/227,P = 0.91)。在未接受环丙沙星预防治疗的自身血液透析受者中,生殖细胞瘤患者发生任何菌血症的概率最高(P=0.09)(43.5%,10/23),其次是淋巴瘤患者(32.5%,13/40)、其他自身血液透析适应症患者(22.2%,2/9)、多发性骨髓瘤患者(22.1%,29/131)和多发性硬化症患者(12.5%,3/24)。生殖细胞肿瘤患者的菌血症数量较高,主要是由革兰氏阴性病原体引起的。环丙沙星预防性治疗可降低异体肝移植受者的革兰氏阴性菌痢疾发病率。因生殖细胞瘤而接受自体肝移植的受者未接受环丙沙星预防治疗,其菌血症发生率最高,可能成为这一干预措施的目标群体。
{"title":"Ciprofloxacin prophylaxis during haematopoietic cell transplantation: a role for use in patients with germ cell tumours?","authors":"Konstantinos Kavallieros, Ioannis Baltas, Giannis Konstantinou, Eirini Koutoumanou, Malick M Gibani, Mark Gilchrist, Frances Davies, Jiri Pavlu","doi":"10.1099/jmm.0.001847","DOIUrl":"10.1099/jmm.0.001847","url":null,"abstract":"<p><p><b>Introduction.</b> Fluoroquinolone prophylaxis during haematopoietic cell transplantation (HCT) can lead to antimicrobial resistance (AMR). Identifying the groups of patients that have the highest likelihood of benefiting from prophylactic antimicrobials is important for antimicrobial stewardship (AMS).<b>Hypothesis.</b> We aimed to identify groups of HCT recipients that have the highest likelihood of benefiting from prophylactic fluroquinolones.<b>Methods.</b> All admissions for HCT in a tertiary centre between January 2020 and December 2022 (<i>N</i> = 400) were retrospectively studied. Allogeneic HCT (allo-HCT) recipients had prophylaxis with ciprofloxacin during the chemotherapy-induced neutropenia, while autologous HCT (auto-HCT) recipients did not. Bacteraemias were recorded when non-contaminant bacterial pathogens were isolated in blood cultures.<b>Results.</b> Allo-HCT was performed for 43.3 % (173/400) of patients and auto-HCT was performed for 56.7 % (227/400). A bacteraemia was documented in 28.3 % (113/400) of cases. Allo-HCT recipients were more likely to have a Gram-positive bacteraemia (20.8%, 36/173, vs 10.1%, 23/227, <i>P</i> = 0.03), while a difference was not observed for Gram-negative bacteraemias (18.5%, 32/173 vs 18.1%, 41/227, <i>P</i> = 0.91). Among auto-HCT recipients not receiving ciprofloxacin prophylaxis, patients with germ cell tumours had the highest probability (<i>P</i> for trend 0.09) of recording any bacteraemia (43.5%, 10/23) followed by patients with lymphomas (32.5%, 13/40), other auto-HCT indications (22.2%, 2/9), multiple myeloma (22.1%, 29/131) and multiple sclerosis (12.5%, 3/24). The higher number of bacteraemias in patients with germ cell tumours was primarily driven by Gram-negative pathogens.<b>Conclusions.</b> Ciprofloxacin prophylaxis was associated with a reduced incidence of Gram-negative bacteraemias in allo-HCT recipients. Auto-HCT recipients due to germ cell tumours, not receiving ciprofloxacin prophylaxis, recorded the highest incidence of bacteraemias and represent a possible target group for this intervention.</p>","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antifungal activity of human antimicrobial peptides targeting apoptosis in Candida auris. 针对白色念珠菌细胞凋亡的人类抗菌肽的抗真菌活性。
Pub Date : 2024-05-01 DOI: 10.1099/jmm.0.001835
Siham Shaban, Mrudula Patel, Aijaz Ahmad

Introduction. Innovative antifungal therapies are of crucial importance to combat the potentially life-threatening infections linked to the multidrug-resistant fungal pathogen Candida auris. Induction of regulated cell death, apoptosis, could provide an outline for future therapeutics. Human antimicrobial peptides (AMPs), well-known antifungal compounds, have shown the ability to induce apoptosis in pathogenic fungi.Hypothesis/Gap Statement . Although it is known that AMPs possess antifungal activity against C. auris, their ability to induce apoptosis requires further investigations.Aim. This study evaluated the effects of AMPs on the induction of apoptosis in C. auris.Methods. Human neutrophil peptide-1 (HNP-1), human β-Defensins-3 (hBD-3) and human salivary histatin 5 (His 5) were assessed against two clinical C. auris isolates. Apoptosis hallmarks were examined using FITC-Annexin V/PI double labelling assay and terminal deoxynucleotidyl transferase deoxynucleotidyl transferase nick-end labelling (TUNEL) to detect phosphatidylserine externalization and DNA fragmentation, respectively. Then, several intracellular triggers were studied using JC-10 staining, spectrophotometric assay and 2',7'-dichlorofluorescin diacetate staining to measure the mitochondrial membrane potential, cytochrome-c release and reactive oxygen species (ROS) production, respectively.Results and conclusion. FITC-Annexin V/PI staining and TUNEL analysis revealed that exposure of C. auris cells to HNP-1 and hBD-3 triggered both early and late apoptosis, while His 5 caused significant necrosis. Furthermore, HNP-1 and hBD-3 induced significant mitochondrial membrane depolarization, which resulted in substantial cytochrome c release. In contrast to His 5, which showed minimal mitochondrial depolarization and no cytochrome c release. At last, all peptides significantly increased ROS production, which is related to both types of cell death. Therefore, these peptides represent promising and effective antifungal agents for treating invasive infections caused by multidrug-resistant C. auris.

导言。创新的抗真菌疗法对于抗击由具有多重耐药性的真菌病原体白色念珠菌引起的可能危及生命的感染至关重要。诱导调节性细胞死亡(细胞凋亡)可以为未来的疗法提供一个轮廓。人类抗菌肽(AMPs)是著名的抗真菌化合物,已显示出诱导病原真菌细胞凋亡的能力。尽管已知 AMPs 具有抗真菌活性,但其诱导细胞凋亡的能力还需要进一步研究。本研究评估了 AMPs 对诱导 C. auris 细胞凋亡的影响。评估了人中性粒细胞肽-1(HNP-1)、人β-防御素-3(hBD-3)和人唾液组蛋白5(His 5)对两种临床阴道杆菌分离物的作用。使用 FITC-Annexin V/PI 双标记检测法和末端脱氧核苷酸转移酶缺刻端标记法(TUNEL)分别检测磷脂酰丝氨酸外化和 DNA 断裂,以检查细胞凋亡标志。然后,使用JC-10染色法、分光光度法和2',7'-二氯荧光素二乙酸酯染色法分别研究了线粒体膜电位、细胞色素-c释放和活性氧(ROS)产生的几种细胞内触发因素。FITC-Annexin V/PI染色和TUNEL分析表明,C. auris细胞暴露于HNP-1和hBD-3会引发早期和晚期细胞凋亡,而His 5则会导致细胞大量坏死。此外,HNP-1 和 hBD-3 还诱导线粒体膜显著去极化,导致大量细胞色素 c 释放。相比之下,His 5 的线粒体去极化程度很小,也没有细胞色素 c 释放。最后,所有肽都能显著增加 ROS 的产生,而 ROS 的产生与两种细胞死亡类型都有关系。因此,这些多肽是治疗耐多药球孢子菌引起的侵袭性感染的有效抗真菌剂。
{"title":"Antifungal activity of human antimicrobial peptides targeting apoptosis in <i>Candida auris</i>.","authors":"Siham Shaban, Mrudula Patel, Aijaz Ahmad","doi":"10.1099/jmm.0.001835","DOIUrl":"https://doi.org/10.1099/jmm.0.001835","url":null,"abstract":"<p><p><b>Introduction.</b> Innovative antifungal therapies are of crucial importance to combat the potentially life-threatening infections linked to the multidrug-resistant fungal pathogen <i>Candida auris</i>. Induction of regulated cell death, apoptosis, could provide an outline for future therapeutics. Human antimicrobial peptides (AMPs), well-known antifungal compounds, have shown the ability to induce apoptosis in pathogenic fungi.<b>Hypothesis/Gap Statement</b> <b>.</b> Although it is known that AMPs possess antifungal activity against <i>C. auris</i>, their ability to induce apoptosis requires further investigations.<b>Aim.</b> This study evaluated the effects of AMPs on the induction of apoptosis in <i>C. auris</i>.<b>Methods.</b> Human neutrophil peptide-1 (HNP-1), human β-Defensins-3 (hBD-3) and human salivary histatin 5 (His 5) were assessed against two clinical <i>C. auris</i> isolates. Apoptosis hallmarks were examined using FITC-Annexin V/PI double labelling assay and terminal deoxynucleotidyl transferase deoxynucleotidyl transferase nick-end labelling (TUNEL) to detect phosphatidylserine externalization and DNA fragmentation, respectively. Then, several intracellular triggers were studied using JC-10 staining, spectrophotometric assay and 2',7'-dichlorofluorescin diacetate staining to measure the mitochondrial membrane potential, cytochrome-c release and reactive oxygen species (ROS) production, respectively.<b>Results and conclusion.</b> FITC-Annexin V/PI staining and TUNEL analysis revealed that exposure of <i>C. auris</i> cells to HNP-1 and hBD-3 triggered both early and late apoptosis, while His 5 caused significant necrosis. Furthermore, HNP-1 and hBD-3 induced significant mitochondrial membrane depolarization, which resulted in substantial cytochrome c release. In contrast to His 5, which showed minimal mitochondrial depolarization and no cytochrome c release. At last, all peptides significantly increased ROS production, which is related to both types of cell death. Therefore, these peptides represent promising and effective antifungal agents for treating invasive infections caused by multidrug-resistant <i>C. auris.</i></p>","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140924052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deletion of codY impairs Staphylococcus epidermidis biofilm formation, generation of viable but non-culturable cells and stimulates cytokine production in human macrophages. 缺失 codY 会影响表皮葡萄球菌生物膜的形成、产生有活力但不可培养的细胞,并刺激人类巨噬细胞产生细胞因子。
Pub Date : 2024-05-01 DOI: 10.1099/jmm.0.001837
Nathalie Lopes, Renato B Pereira, Alexandra Correia, Manuel Vilanova, Nuno Cerca, Angela França

Introduction. Staphylococcus epidermidis biofilms are one of the major causes of bloodstream infections related to the use of medical devices. The diagnosis of these infections is challenging, delaying their treatment and resulting in increased morbidity and mortality rates. As such, it is urgent to characterize the mechanisms employed by this bacterium to endure antibiotic treatments and the response of the host immune system, to develop more effective therapeutic strategies. In several bacterial species, the gene codY was shown to encode a protein that regulates the expression of genes involved in biofilm formation and immune evasion. Additionally, in a previous study, our group generated evidence indicating that codY is involved in the emergence of viable but non-culturable (VBNC) cells in S. epidermidis.Gap statement/Hypothesis. As such, we hypothesized that the gene codY has have an important role in this bacterium virulence.Aim. This study aimed to assess, for the first time, the impact of the deletion of the gene codY in S. epidermidis virulence, namely, in antibiotic susceptibility, biofilm formation, VBNC state emergence and in vitro host immune system response.Methodology. Using an allelic replacement strategy, we constructed and then characterized an S. epidermidis strain lacking codY, in regards to biofilm and VBNC cell formation, susceptibility to antibiotics as well as their role in the interaction with human blood and plasma. Additionally, we investigate whether the codY gene can impact the activation of innate immune cells by evaluating the production of both pro- and anti-inflammatory cytokines by THP-1 macrophages.Results. We demonstrated that the deletion of the gene codY resulted in biofilms with less c.f.u. counts and fewer VBNC cells. Furthermore, we show that although WT and mutant cells were similarly internalized in vitro by human macrophages, a stronger cytokine response was elicited by the mutant in a toll-like receptor 4-dependent manner.Conclusion. Our results indicate that codY contributes to S. epidermidis virulence, which in turn may have an impact on our ability to manage the biofilm-associated infections caused by this bacterium.

导言。表皮葡萄球菌生物膜是与使用医疗器械有关的血液感染的主要原因之一。这些感染的诊断极具挑战性,不仅延误了治疗,还导致发病率和死亡率上升。因此,当务之急是研究这种细菌耐受抗生素治疗和宿主免疫系统反应的机制,以开发更有效的治疗策略。在一些细菌物种中,codY 基因被证明编码一种蛋白质,它能调节参与生物膜形成和免疫逃避的基因的表达。此外,在之前的一项研究中,我们小组获得的证据表明,codY 参与了表皮葡萄球菌中可存活但不可培养(VBNC)细胞的出现。因此,我们假设 codY 基因在该细菌的毒力中发挥了重要作用。本研究旨在首次评估缺失 codY 基因对表皮葡萄球菌毒力的影响,即对抗生素的敏感性、生物膜的形成、VBNC 状态的出现以及体外宿主免疫系统的反应。通过等位基因替换策略,我们构建了缺乏 codY 的表皮葡萄球菌菌株,并对其生物膜和 VBNC 细胞的形成、对抗生素的敏感性及其在与人体血液和血浆相互作用中的作用进行了鉴定。此外,我们还通过评估 THP-1 巨噬细胞产生的促炎和抗炎细胞因子,研究了 codY 基因是否会影响先天性免疫细胞的激活。结果表明,codY 基因缺失会导致生物膜中的 c.f.u. 数量减少,VBNC 细胞减少。此外,我们还发现,虽然 WT 细胞和突变体细胞在体外被人类巨噬细胞内化的情况相似,但突变体细胞以依赖于收费样受体 4 的方式引起了更强的细胞因子反应。我们的研究结果表明,codY 有助于提高表皮葡萄球菌的毒力,这反过来可能会影响我们管理由这种细菌引起的生物膜相关感染的能力。
{"title":"Deletion of <i>codY</i> impairs <i>Staphylococcus epidermidis</i> biofilm formation, generation of viable but non-culturable cells and stimulates cytokine production in human macrophages.","authors":"Nathalie Lopes, Renato B Pereira, Alexandra Correia, Manuel Vilanova, Nuno Cerca, Angela França","doi":"10.1099/jmm.0.001837","DOIUrl":"10.1099/jmm.0.001837","url":null,"abstract":"<p><p><b>Introduction.</b> <i>Staphylococcus epidermidis</i> biofilms are one of the major causes of bloodstream infections related to the use of medical devices. The diagnosis of these infections is challenging, delaying their treatment and resulting in increased morbidity and mortality rates. As such, it is urgent to characterize the mechanisms employed by this bacterium to endure antibiotic treatments and the response of the host immune system, to develop more effective therapeutic strategies. In several bacterial species, the gene <i>codY</i> was shown to encode a protein that regulates the expression of genes involved in biofilm formation and immune evasion. Additionally, in a previous study, our group generated evidence indicating that <i>codY</i> is involved in the emergence of viable but non-culturable (VBNC) cells in <i>S. epidermidis</i>.<b>Gap statement/Hypothesis.</b> As such, we hypothesized that the gene codY has have an important role in this bacterium virulence.<b>Aim.</b> This study aimed to assess, for the first time, the impact of the deletion of the gene <i>codY</i> in <i>S. epidermidis</i> virulence, namely, in antibiotic susceptibility, biofilm formation, VBNC state emergence and <i>in vitro</i> host immune system response.<b>Methodology.</b> Using an allelic replacement strategy, we constructed and then characterized an <i>S. epidermidis</i> strain lacking <i>codY,</i> in regards to biofilm and VBNC cell formation, susceptibility to antibiotics as well as their role in the interaction with human blood and plasma. Additionally, we investigate whether the <i>codY</i> gene can impact the activation of innate immune cells by evaluating the production of both pro- and anti-inflammatory cytokines by THP-1 macrophages.<b>Results.</b> We demonstrated that the deletion of the gene <i>codY</i> resulted in biofilms with less c.f.u. counts and fewer VBNC cells. Furthermore, we show that although WT and mutant cells were similarly internalized <i>in vitro</i> by human macrophages, a stronger cytokine response was elicited by the mutant in a toll-like receptor 4-dependent manner.<b>Conclusion.</b> Our results indicate that <i>codY</i> contributes to <i>S. epidermidis</i> virulence, which in turn may have an impact on our ability to manage the biofilm-associated infections caused by this bacterium.</p>","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140924015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England. 念珠菌的实验室调查、管理和感染预防与控制:为英格兰 2024 年国家指南更新提供信息的叙述性综述。
Pub Date : 2024-05-01 DOI: 10.1099/jmm.0.001820
Christopher R Jones, Claire Neill, Andrew M Borman, Emma L Budd, Martina Cummins, Carole Fry, Rebecca L Guy, Katie Jeffery, Elizabeth M Johnson, Rohini Manuel, Mariyam Mirfenderesky, Ginny Moore, Bharat Patel, Silke Schelenz, Karren Staniforth, Surabhi K Taori, Colin S Brown

The emergent fungal pathogen Candida auris is increasingly recognised as an important cause of healthcare-associated infections globally. It is highly transmissible, adaptable, and persistent, resulting in an organism with significant outbreak potential that risks devastating consequences. Progress in the ability to identify C. auris in clinical specimens is encouraging, but laboratory diagnostic capacity and surveillance systems are lacking in many countries. Intrinsic resistance to commonly used antifungals, combined with the ability to rapidly acquire resistance to therapy, substantially restricts treatment options and novel agents are desperately needed. Despite this, outbreaks can be interrupted, and mortality avoided or minimised, through the application of rigorous infection prevention and control measures with an increasing evidence base. This review provides an update on epidemiology, the impact of the COVID-19 pandemic, risk factors, identification and typing, resistance profiles, treatment, detection of colonisation, and infection prevention and control measures for C. auris. This review has informed a planned 2024 update to the United Kingdom Health Security Agency (UKHSA) guidance on the laboratory investigation, management, and infection prevention and control of Candida auris. A multidisciplinary response is needed to control C. auris transmission in a healthcare setting and should emphasise outbreak preparedness and response, rapid contact tracing and isolation or cohorting of patients and staff, strict hand hygiene and other infection prevention and control measures, dedicated or single-use equipment, appropriate disinfection, and effective communication concerning patient transfers and discharge.

新出现的真菌病原体白色念珠菌越来越被认为是全球医疗相关感染的一个重要原因。念珠菌具有高度传播性、适应性和持久性,是一种极有可能导致灾难性后果的病菌。从临床标本中识别法氏囊病菌的能力取得了令人鼓舞的进展,但许多国家缺乏实验室诊断能力和监测系统。对常用抗真菌药物的内在抗药性,再加上快速获得抗药性的能力,大大限制了治疗方案的选择,因此迫切需要新型药物。尽管如此,在越来越多的证据基础上,通过采取严格的感染预防和控制措施,还是可以阻断疾病的爆发,避免或最大限度地降低死亡率。本综述提供了有关流行病学、COVID-19 大流行的影响、风险因素、识别和分型、耐药性特征、治疗、定植检测以及阿氏杆菌感染预防和控制措施的最新信息。此次审查为英国卫生安全局(UKHSA)计划于 2024 年更新有关实验室调查、管理和感染预防与控制念珠菌的指南提供了依据。要控制念珠菌在医疗机构中的传播,需要采取多学科应对措施,并应强调疫情准备和应对、快速追踪接触者、隔离或集中患者和工作人员、严格的手部卫生和其他感染预防与控制措施、专用或一次性设备、适当的消毒以及有关患者转院和出院的有效沟通。
{"title":"The laboratory investigation, management, and infection prevention and control of <i>Candida auris</i>: a narrative review to inform the 2024 national guidance update in England.","authors":"Christopher R Jones, Claire Neill, Andrew M Borman, Emma L Budd, Martina Cummins, Carole Fry, Rebecca L Guy, Katie Jeffery, Elizabeth M Johnson, Rohini Manuel, Mariyam Mirfenderesky, Ginny Moore, Bharat Patel, Silke Schelenz, Karren Staniforth, Surabhi K Taori, Colin S Brown","doi":"10.1099/jmm.0.001820","DOIUrl":"10.1099/jmm.0.001820","url":null,"abstract":"<p><p>The emergent fungal pathogen <i>Candida auris</i> is increasingly recognised as an important cause of healthcare-associated infections globally. It is highly transmissible, adaptable, and persistent, resulting in an organism with significant outbreak potential that risks devastating consequences. Progress in the ability to identify <i>C. auris</i> in clinical specimens is encouraging, but laboratory diagnostic capacity and surveillance systems are lacking in many countries. Intrinsic resistance to commonly used antifungals, combined with the ability to rapidly acquire resistance to therapy, substantially restricts treatment options and novel agents are desperately needed. Despite this, outbreaks can be interrupted, and mortality avoided or minimised, through the application of rigorous infection prevention and control measures with an increasing evidence base. This review provides an update on epidemiology, the impact of the COVID-19 pandemic, risk factors, identification and typing, resistance profiles, treatment, detection of colonisation, and infection prevention and control measures for <i>C. auris</i>. This review has informed a planned 2024 update to the United Kingdom Health Security Agency (UKHSA) guidance on the laboratory investigation, management, and infection prevention and control of <i>Candida auris</i>. A multidisciplinary response is needed to control <i>C. auris</i> transmission in a healthcare setting and should emphasise outbreak preparedness and response, rapid contact tracing and isolation or cohorting of patients and staff, strict hand hygiene and other infection prevention and control measures, dedicated or single-use equipment, appropriate disinfection, and effective communication concerning patient transfers and discharge.</p>","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11165919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic stewardship in infectious diseases: a scoping review. 传染病诊断管理:范围综述。
Pub Date : 2024-05-01 DOI: 10.1099/jmm.0.001831
Robert Shorten, Kate Pickering, Callum Goolden, Catherine Harris, Andrew Clegg, Hill J

Introduction. The term 'diagnostic stewardship' is relatively new, with a recent surge in its use within the literature. Despite its increasing popularity, a precise definition remains elusive. Various attempts have been made to define it, with some viewing it as an integral part of antimicrobial stewardship. The World Health Organization offers a broad definition, emphasizing the importance of timely, accurate diagnostics. However, inconsistencies in the use of this term still persist, necessitating further clarification.Gap Statement. There are currently inconsistencies in the definition of diagnostic stewardship used within the academic literature.Aim. This scoping review aims to categorize the use of diagnostic stewardship approaches and define this approach by identifying common characteristics and factors of its use within the literature.Methodology. This scoping review undertook a multi-database search from date of inception until October 2022. Any observational or experimental study where the authors define the intervention to be diagnostic stewardship from any clinical area was included. Screening of all papers was undertaken by a single reviewer with 10% verification by a second reviewer. Data extraction was undertaken by a single reviewer using a pre-piloted form. Given the wide variation in study design and intervention outcomes, a narrative synthesis approach was applied. Studies were clustered around common diagnostic stewardship interventions where appropriate.Results. After duplicate removal, a total of 1310 citations were identified, of which, after full-paper screening, 105 studies were included in this scoping review. The classification of an intervention as taking a diagnostic stewardship approach is a relatively recent development, with the first publication in this field dating back to 2017. The majority of research in this area has been conducted within the USA, with very few studies undertaken outside this region. Visual inspection of the citation map reveals that the current evidence base is interconnected, with frequent references to each other's work. The interventions commonly adopt a restrictive approach, utilizing hard and soft stops within the pre-analytical phase to restrict access to testing. Upon closer examination of the outcomes, it becomes evident that there is a predominant focus on reducing the number of tests rather than enhancing the current test protocol. This is further reflected in the limited number of studies that report on test performance (including protocol improvements, specificity and sensitivity).Conclusion. Diagnostic stewardship seems to have deviated from its intended course, morphing into a rather rudimentary instrument wielded not to enhance but to constrict the scope of testing. Despite the World Health Organization's advocacy for an ideology that promotes a more comprehensive approach to quality improvement, it may be more appropriate to con

引言。诊断监管 "是一个相对较新的术语,最近在文献中的使用激增。尽管它越来越受欢迎,但准确的定义仍然难以确定。人们曾多次尝试对其进行定义,其中一些人将其视为抗菌药物监管的一个组成部分。世界卫生组织给出了一个宽泛的定义,强调了及时、准确诊断的重要性。然而,这一术语的使用仍存在不一致之处,有必要进一步加以澄清。目前,学术文献中使用的诊断监管定义并不一致。本范围界定综述旨在对诊断监管方法的使用进行分类,并通过确定文献中使用该方法的共同特征和因素来定义该方法。本范围界定综述进行了多数据库检索,检索时间从开始日期起至 2022 年 10 月。作者将任何临床领域的干预定义为诊断监管的观察性或实验性研究均被纳入其中。所有论文均由一名审稿人进行筛选,并由第二名审稿人进行 10% 的核实。数据提取由一名审稿人使用预先试写的表格进行。鉴于研究设计和干预结果差异很大,因此采用了叙事综合法。在适当的情况下,围绕常见的诊断管理干预措施对研究进行了分组。去除重复内容后,共发现了 1310 条引文,其中 105 项研究经过论文全文筛选后纳入了本范围界定综述。将一项干预措施归类为诊断监管方法是一项相对较新的发展,该领域的第一篇论文发表于2017年。该领域的大部分研究都是在美国进行的,在该地区以外进行的研究很少。对引文图的目视检查显示,目前的证据基础是相互关联的,彼此的研究成果经常被引用。干预措施通常采用限制性方法,在分析前阶段利用硬性和软性制止措施来限制接受检测。在对结果进行更仔细的研究后,我们会发现,这些干预措施的主要重点是减少检测次数,而不是加强当前的检测方案。这进一步反映在报告检验性能(包括方案改进、特异性和灵敏度)的研究数量有限。诊断监管似乎已经偏离了它的初衷,变成了一种相当初级的工具,不是用来加强而是用来限制检测范围。尽管世界卫生组织倡导以更全面的方法来提高质量,但在对这类质量改进措施进行分类时,考虑其他地区的说法可能更为恰当。
{"title":"Diagnostic stewardship in infectious diseases: a scoping review.","authors":"Robert Shorten, Kate Pickering, Callum Goolden, Catherine Harris, Andrew Clegg, Hill J","doi":"10.1099/jmm.0.001831","DOIUrl":"10.1099/jmm.0.001831","url":null,"abstract":"<p><p><b>Introduction.</b> The term 'diagnostic stewardship' is relatively new, with a recent surge in its use within the literature. Despite its increasing popularity, a precise definition remains elusive. Various attempts have been made to define it, with some viewing it as an integral part of antimicrobial stewardship. The World Health Organization offers a broad definition, emphasizing the importance of timely, accurate diagnostics. However, inconsistencies in the use of this term still persist, necessitating further clarification.<b>Gap Statement.</b> There are currently inconsistencies in the definition of diagnostic stewardship used within the academic literature.<b>Aim.</b> This scoping review aims to categorize the use of diagnostic stewardship approaches and define this approach by identifying common characteristics and factors of its use within the literature.<b>Methodology.</b> This scoping review undertook a multi-database search from date of inception until October 2022. Any observational or experimental study where the authors define the intervention to be diagnostic stewardship from any clinical area was included. Screening of all papers was undertaken by a single reviewer with 10% verification by a second reviewer. Data extraction was undertaken by a single reviewer using a pre-piloted form. Given the wide variation in study design and intervention outcomes, a narrative synthesis approach was applied. Studies were clustered around common diagnostic stewardship interventions where appropriate.<b>Results.</b> After duplicate removal, a total of 1310 citations were identified, of which, after full-paper screening, 105 studies were included in this scoping review. The classification of an intervention as taking a diagnostic stewardship approach is a relatively recent development, with the first publication in this field dating back to 2017. The majority of research in this area has been conducted within the USA, with very few studies undertaken outside this region. Visual inspection of the citation map reveals that the current evidence base is interconnected, with frequent references to each other's work. The interventions commonly adopt a restrictive approach, utilizing hard and soft stops within the pre-analytical phase to restrict access to testing. Upon closer examination of the outcomes, it becomes evident that there is a predominant focus on reducing the number of tests rather than enhancing the current test protocol. This is further reflected in the limited number of studies that report on test performance (including protocol improvements, specificity and sensitivity).<b>Conclusion.</b> Diagnostic stewardship seems to have deviated from its intended course, morphing into a rather rudimentary instrument wielded not to enhance but to constrict the scope of testing. Despite the World Health Organization's advocacy for an ideology that promotes a more comprehensive approach to quality improvement, it may be more appropriate to con","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11165918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The emergence and circulation of human immunodeficiency virus (HIV)-1 subtype C. 人体免疫缺陷病毒(HIV)-1 亚型 C 的出现和传播。
Pub Date : 2024-05-01 DOI: 10.1099/jmm.0.001827
Xingguang Li, Sana Tamim, Nídia S Trovão
Introduction. Human immunodeficiency virus (HIV)-1 subtype C is the most prevalent globally and is thought to have originated in non-human primates in the Democratic Republic of Congo.Hypothesis/Gap Statement. Although the global dominance of HIV-1 subtype C is well established, a thorough understanding of its evolutionary history and transmission dynamics across various risk populations remains elusive. The current knowledge is insufficient to fully capture the global diversification and dissemination of this subtype.Aim. We for the first time sought to investigate the global evolutionary history and spatiotemporal dynamics of HIV-1 subtype C using a selection of maximum-likelihood-based phylodynamic approaches on a total of 1210 near full-length genomic sequences sampled from 32 countries, collected in 4 continents, with sampling dates between 1986-2019 among various risk groups were analysed.Methodology. We subsampled the HIV-1 subtype C genomic datasets based on continent and risk group traits, and performed nucleotide substitution model selection analysis, maximum likelihood (ML) phylogenetic reconstruction, phylogenetic tree topology similarity analysis, temporal signal analysis and traced the timings of viral spread both geographically and by risk group.Results. Based on the phylodynamic analyses of four datasets (full1210, locrisk626, loc562 and risk393), we inferred the time to the most recent common ancestor (TMRCA) in the 1930s and an evolutionary rate of 0.0023 substitutions per site per year. The total number of introduction events of HIV-1 subtype C between continents and between risk groups is estimated to be 71 and 115, respectively. The largest number of introductions occurred from Africa to Europe (n=32), from not-recorded to heterosexual (n=40) and from heterosexual to not-recorded (n=51) risk groups.Conclusion. Our results emphasize that HIV subtype C has mainly spread from Africa to Europe, likely through heterosexual transmission.
导言。人类免疫缺陷病毒(HIV)-1 亚型 C 是全球最流行的病毒,被认为起源于刚果民主共和国的非人灵长类。尽管 HIV-1 亚型 C 在全球占主导地位的事实已得到证实,但对其进化史和在不同风险人群中的传播动态仍缺乏透彻的了解。目前的知识不足以全面了解该亚型在全球的多样化和传播情况。我们首次采用基于最大似然法的系统动力学方法,对来自 4 大洲 32 个国家、采样日期在 1986-2019 年间的 1210 个近全长基因组序列进行了分析,试图研究 HIV-1 亚型 C 的全球进化史和时空动态。我们根据各大洲和风险组特征对HIV-1亚型C基因组数据集进行了子取样,并进行了核苷酸替换模型选择分析、最大似然(ML)系统发育重建、系统发育树拓扑相似性分析、时间信号分析,并按地域和风险组追踪了病毒传播的时间。根据对四个数据集(full1210、locrisk626、loc562和risk393)的系统动力学分析,我们推断出距最近共同祖先(TMRCA)的时间为20世纪30年代,进化速度为每年每个位点0.0023个取代。据估计,HIV-1 亚型 C 在各大洲之间和风险群体之间的引入事件总数分别为 71 次和 115 次。从非洲到欧洲(32 例)、从未记录到异性恋(40 例)以及从异性恋到未记录(51 例)风险群体之间的引入数量最多。我们的研究结果表明,艾滋病毒 C 亚型主要是从非洲传播到欧洲,很可能是通过异性性传播。
{"title":"The emergence and circulation of human immunodeficiency virus (HIV)-1 subtype C.","authors":"Xingguang Li, Sana Tamim, Nídia S Trovão","doi":"10.1099/jmm.0.001827","DOIUrl":"https://doi.org/10.1099/jmm.0.001827","url":null,"abstract":"Introduction. Human immunodeficiency virus (HIV)-1 subtype C is the most prevalent globally and is thought to have originated in non-human primates in the Democratic Republic of Congo.Hypothesis/Gap Statement. Although the global dominance of HIV-1 subtype C is well established, a thorough understanding of its evolutionary history and transmission dynamics across various risk populations remains elusive. The current knowledge is insufficient to fully capture the global diversification and dissemination of this subtype.Aim. We for the first time sought to investigate the global evolutionary history and spatiotemporal dynamics of HIV-1 subtype C using a selection of maximum-likelihood-based phylodynamic approaches on a total of 1210 near full-length genomic sequences sampled from 32 countries, collected in 4 continents, with sampling dates between 1986-2019 among various risk groups were analysed.Methodology. We subsampled the HIV-1 subtype C genomic datasets based on continent and risk group traits, and performed nucleotide substitution model selection analysis, maximum likelihood (ML) phylogenetic reconstruction, phylogenetic tree topology similarity analysis, temporal signal analysis and traced the timings of viral spread both geographically and by risk group.Results. Based on the phylodynamic analyses of four datasets (full1210, locrisk626, loc562 and risk393), we inferred the time to the most recent common ancestor (TMRCA) in the 1930s and an evolutionary rate of 0.0023 substitutions per site per year. The total number of introduction events of HIV-1 subtype C between continents and between risk groups is estimated to be 71 and 115, respectively. The largest number of introductions occurred from Africa to Europe (n=32), from not-recorded to heterosexual (n=40) and from heterosexual to not-recorded (n=51) risk groups.Conclusion. Our results emphasize that HIV subtype C has mainly spread from Africa to Europe, likely through heterosexual transmission.","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"35 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141039094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dengue: A review of laboratory diagnostics in the vaccine age. 登革热:疫苗时代的实验室诊断综述。
Pub Date : 2024-05-01 DOI: 10.1099/jmm.0.001833
Jaimie L Frazer, Robert Norton

Background. Dengue is an important arboviral infection of considerable public health significance. It occurs in a wide global belt within a variety of tropical regions. The timely laboratory diagnosis of Dengue infection is critical to inform both clinical management and an appropriate public health response. Vaccination against Dengue virus is being introduced in some areas.Discussion. Appropriate diagnostic strategies will vary between laboratories depending on the available resources and skills. Diagnostic methods available include viral culture, the serological detection of Dengue-specific antibodies in using enzyme immunoassays (EIAs), microsphere immunoassays, haemagglutination inhibition or in lateral flow point of care tests. The results of antibody tests may be influenced by prior vaccination and exposure to other flaviviruses. The detection of non-structural protein 1 in serum (NS1) has improved the early diagnosis of Dengue and is available in point-of-care assays in addition to EIAs. Direct detection of viral RNA from blood by PCR is more sensitive than NS1 antigen detection but requires molecular skills and resources. An increasing variety of isothermal nucleic acid detection methods are in development. Timing of specimen collection and choice of test is critical to optimize diagnostic accuracy. Metagenomics and the direct detection by sequencing of viral RNA from blood offers the ability to rapidly type isolates for epidemiologic purposes.Conclusion. The impact of vaccination on immune response must be recognized as it will impact test interpretation and diagnostic algorithms.

背景。登革热是一种重要的虫媒病毒感染,对公共卫生具有重大意义。它在全球多个热带地区广泛流行。登革热感染的及时实验室诊断对于临床治疗和适当的公共卫生应对措施至关重要。一些地区正在引入登革热病毒疫苗接种。不同实验室的适当诊断策略各不相同,这取决于实验室的可用资源和技能。现有的诊断方法包括病毒培养、使用酶免疫测定法(EIA)、微球免疫测定法、血凝抑制法或侧流护理点检测法进行登革热特异性抗体的血清学检测。抗体检测结果可能会受到之前接种疫苗和接触其他黄病毒的影响。检测血清中的非结构蛋白 1(NS1)提高了登革热的早期诊断率,除 EIA 外,还可用于护理点检测。通过 PCR 直接检测血液中的病毒 RNA 比检测 NS1 抗原更灵敏,但需要分子技能和资源。目前正在开发越来越多的等温核酸检测方法。标本采集的时机和检测方法的选择对于优化诊断准确性至关重要。元基因组学和通过测序直接检测血液中的病毒 RNA 可为流行病学目的提供快速分型的能力。必须认识到接种疫苗对免疫反应的影响,因为这将影响检验解释和诊断算法。
{"title":"Dengue: A review of laboratory diagnostics in the vaccine age.","authors":"Jaimie L Frazer, Robert Norton","doi":"10.1099/jmm.0.001833","DOIUrl":"10.1099/jmm.0.001833","url":null,"abstract":"<p><p><b>Background.</b> Dengue is an important arboviral infection of considerable public health significance. It occurs in a wide global belt within a variety of tropical regions. The timely laboratory diagnosis of Dengue infection is critical to inform both clinical management and an appropriate public health response. Vaccination against Dengue virus is being introduced in some areas.<b>Discussion.</b> Appropriate diagnostic strategies will vary between laboratories depending on the available resources and skills. Diagnostic methods available include viral culture, the serological detection of Dengue-specific antibodies in using enzyme immunoassays (EIAs), microsphere immunoassays, haemagglutination inhibition or in lateral flow point of care tests. The results of antibody tests may be influenced by prior vaccination and exposure to other flaviviruses. The detection of non-structural protein 1 in serum (NS1) has improved the early diagnosis of Dengue and is available in point-of-care assays in addition to EIAs. Direct detection of viral RNA from blood by PCR is more sensitive than NS1 antigen detection but requires molecular skills and resources. An increasing variety of isothermal nucleic acid detection methods are in development. Timing of specimen collection and choice of test is critical to optimize diagnostic accuracy. Metagenomics and the direct detection by sequencing of viral RNA from blood offers the ability to rapidly type isolates for epidemiologic purposes.<b>Conclusion.</b> The impact of vaccination on immune response must be recognized as it will impact test interpretation and diagnostic algorithms.</p>","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic variations of penicillin-binding protein 1A: insights into the current status of amoxicillin-based regimens for Helicobacter pylori eradication in Malaysia. 青霉素结合蛋白 1A 的基因变异:马来西亚以阿莫西林为基础的根除幽门螺旋杆菌疗法现状的启示。
Pub Date : 2024-05-01 DOI: 10.1099/jmm.0.001832
Heng Kang Ng, Kek Heng Chua, Boon Pin Kee, Kee Huat Chuah, Lip Yee Por, Suat Moi Puah

Introduction. Resistance towards amoxicillin in Helicobacter pylori causes significant therapeutic impasse in healthcare settings worldwide. In Malaysia, the standard H. pylori treatment regimen includes a 14-day course of high-dose proton-pump inhibitor (rabeprazole, 20 mg) with amoxicillin (1000 mg) dual therapy.Hypothesis/Gap Statement. The high eradication rate with amoxicillin-based treatment could be attributed to the primary resistance rates of amoxicillin being relatively low at 0%, however, a low rate of secondary resistance has been documented in Malaysia recently.Aim. This study aims to investigate the amino acid mutations and related genetic variants in PBP1A of H. pylori, correlating with amoxicillin resistance in the Malaysian population.Methodology. The full-length pbp1A gene was amplified via PCR from 50 genomic DNA extracted from gastric biopsy samples of H. pylori-positive treatment-naïve Malaysian patients. The sequences were then compared with reference H. pylori strain ATCC 26695 for mutation and variant detection. A phylogenetic analysis of 50 sequences along with 43 additional sequences from the NCBI database was performed. These additional sequences included both amoxicillin-resistant strains (n=20) and amoxicillin-sensitive strains (n=23).Results. There was a total of 21 variants of amino acids, with three of them located in or near the PBP-motif (SKN402-404). The percentages of these three variants are as follows: K403X, 2%; S405I, 2% and E406K, 16%. Based on the genetic markers identified, the resistance rate for amoxicillin in our sample remained at 0%. The phylogenetic examination suggested that H. pylori might exhibit unique conserved pbp1A sequences within the Malaysian context.Conclusions. Overall, the molecular analysis of PBP1A supported the therapeutic superiority of amoxicillin-based regimens. Therefore, it is crucial to continue monitoring the amoxicillin resistance background of H. pylori with a larger sample size to ensure the sustained effectiveness of amoxicillin-based treatments in Malaysia.

导言。幽门螺旋杆菌对阿莫西林的耐药性导致全球医疗机构的治疗陷入僵局。在马来西亚,幽门螺杆菌的标准治疗方案包括为期14天的大剂量质子泵抑制剂(雷贝拉唑,20毫克)和阿莫西林(1000毫克)双重疗法。以阿莫西林为基础的治疗具有较高的根除率,这可能是由于阿莫西林的原发性耐药率相对较低,仅为0%,然而,最近在马来西亚也有低继发性耐药率的记录。本研究旨在调查马来西亚人群中幽门螺杆菌 PBP1A 的氨基酸突变和相关基因变异与阿莫西林耐药性的相关性。从马来西亚幽门螺杆菌阳性、未经治疗的患者的胃活检样本中提取 50 个基因组 DNA,通过 PCR 扩增出全长 pbp1A 基因。然后将序列与参考幽门螺杆菌菌株 ATCC 26695 进行比较,以检测突变和变异。对 50 个序列和来自 NCBI 数据库的 43 个附加序列进行了系统发生学分析。这些额外的序列包括耐阿莫西林菌株(n=20)和阿莫西林敏感菌株(n=23)。共有 21 个氨基酸变体,其中三个位于 PBP-motif(SKN402-404)或其附近。这三种变体的百分比如下:K403X,2%;S405I,2%;E406K,16%。根据已确定的遗传标记,样本中阿莫西林的耐药率仍为 0%。系统发生学研究表明,幽门螺杆菌在马来西亚可能表现出独特的pbp1A保守序列。总之,PBP1A 的分子分析支持了以阿莫西林为基础的治疗方案的优越性。因此,继续监测幽门螺杆菌的阿莫西林耐药性背景并扩大样本量以确保阿莫西林疗法在马来西亚的持续有效性至关重要。
{"title":"Genetic variations of penicillin-binding protein 1A: insights into the current status of amoxicillin-based regimens for <i>Helicobacter pylori</i> eradication in Malaysia.","authors":"Heng Kang Ng, Kek Heng Chua, Boon Pin Kee, Kee Huat Chuah, Lip Yee Por, Suat Moi Puah","doi":"10.1099/jmm.0.001832","DOIUrl":"10.1099/jmm.0.001832","url":null,"abstract":"<p><p><b>Introduction.</b> Resistance towards amoxicillin in <i>Helicobacter pylori</i> causes significant therapeutic impasse in healthcare settings worldwide. In Malaysia, the standard <i>H. pylori</i> treatment regimen includes a 14-day course of high-dose proton-pump inhibitor (rabeprazole, 20 mg) with amoxicillin (1000 mg) dual therapy.<b>Hypothesis/Gap Statement.</b> The high eradication rate with amoxicillin-based treatment could be attributed to the primary resistance rates of amoxicillin being relatively low at 0%, however, a low rate of secondary resistance has been documented in Malaysia recently.<b>Aim.</b> This study aims to investigate the amino acid mutations and related genetic variants in PBP1A of <i>H. pylori</i>, correlating with amoxicillin resistance in the Malaysian population.<b>Methodology.</b> The full-length <i>pbp1A</i> gene was amplified via PCR from 50 genomic DNA extracted from gastric biopsy samples of <i>H. pylori</i>-positive treatment-naïve Malaysian patients. The sequences were then compared with reference <i>H. pylori</i> strain ATCC 26695 for mutation and variant detection. A phylogenetic analysis of 50 sequences along with 43 additional sequences from the NCBI database was performed. These additional sequences included both amoxicillin-resistant strains (<i>n</i>=20) and amoxicillin-sensitive strains (<i>n</i>=23).<b>Results.</b> There was a total of 21 variants of amino acids, with three of them located in or near the PBP-motif (SKN402-404). The percentages of these three variants are as follows: K403X, 2%; S405I, 2% and E406K, 16%. Based on the genetic markers identified, the resistance rate for amoxicillin in our sample remained at 0%. The phylogenetic examination suggested that <i>H. pylori</i> might exhibit unique conserved <i>pbp1A</i> sequences within the Malaysian context.<b>Conclusions.</b> Overall, the molecular analysis of PBP1A supported the therapeutic superiority of amoxicillin-based regimens. Therefore, it is crucial to continue monitoring the amoxicillin resistance background of <i>H. pylori</i> with a larger sample size to ensure the sustained effectiveness of amoxicillin-based treatments in Malaysia.</p>","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140875130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The emergence and circulation of human immunodeficiency virus (HIV)-1 subtype C. 人体免疫缺陷病毒(HIV)-1 亚型 C 的出现和传播。
Pub Date : 2024-05-01 DOI: 10.1099/jmm.0.001827
Xingguang Li, Sana Tamim, Nídia S Trovão

Introduction. Human immunodeficiency virus (HIV)-1 subtype C is the most prevalent globally and is thought to have originated in non-human primates in the Democratic Republic of Congo.Hypothesis/Gap Statement. Although the global dominance of HIV-1 subtype C is well established, a thorough understanding of its evolutionary history and transmission dynamics across various risk populations remains elusive. The current knowledge is insufficient to fully capture the global diversification and dissemination of this subtype.Aim. We for the first time sought to investigate the global evolutionary history and spatiotemporal dynamics of HIV-1 subtype C using a selection of maximum-likelihood-based phylodynamic approaches on a total of 1210 near full-length genomic sequences sampled from 32 countries, collected in 4 continents, with sampling dates between 1986-2019 among various risk groups were analysed.Methodology. We subsampled the HIV-1 subtype C genomic datasets based on continent and risk group traits, and performed nucleotide substitution model selection analysis, maximum likelihood (ML) phylogenetic reconstruction, phylogenetic tree topology similarity analysis, temporal signal analysis and traced the timings of viral spread both geographically and by risk group.Results. Based on the phylodynamic analyses of four datasets (full1210, locrisk626, loc562 and risk393), we inferred the time to the most recent common ancestor (TMRCA) in the 1930s and an evolutionary rate of 0.0023 substitutions per site per year. The total number of introduction events of HIV-1 subtype C between continents and between risk groups is estimated to be 71 and 115, respectively. The largest number of introductions occurred from Africa to Europe (n=32), from not-recorded to heterosexual (n=40) and from heterosexual to not-recorded (n=51) risk groups.Conclusion. Our results emphasize that HIV subtype C has mainly spread from Africa to Europe, likely through heterosexual transmission.

导言。人类免疫缺陷病毒(HIV)-1 亚型 C 是全球最流行的病毒,被认为起源于刚果民主共和国的非人灵长类。尽管 HIV-1 亚型 C 在全球占主导地位的事实已得到证实,但对其进化史和在不同风险人群中的传播动态仍缺乏透彻的了解。目前的知识不足以全面了解该亚型在全球的多样化和传播情况。我们首次采用基于最大似然法的系统动力学方法,对来自 4 大洲 32 个国家、采样日期在 1986-2019 年间的 1210 个近全长基因组序列进行了分析,试图研究 HIV-1 亚型 C 的全球进化史和时空动态。我们根据各大洲和风险组特征对HIV-1亚型C基因组数据集进行了子取样,并进行了核苷酸替换模型选择分析、最大似然(ML)系统发育重建、系统发育树拓扑相似性分析、时间信号分析,并按地域和风险组追踪了病毒传播的时间。根据对四个数据集(full1210、locrisk626、loc562和risk393)的系统动力学分析,我们推断出距最近共同祖先(TMRCA)的时间为20世纪30年代,进化速度为每年每个位点0.0023个取代。据估计,HIV-1 亚型 C 在各大洲之间和风险群体之间的引入事件总数分别为 71 次和 115 次。从非洲到欧洲(32 例)、从未记录到异性恋(40 例)以及从异性恋到未记录(51 例)风险群体之间的引入数量最多。我们的研究结果表明,艾滋病毒 C 亚型主要是从非洲传播到欧洲的,很可能是通过异性性传播。
{"title":"The emergence and circulation of human immunodeficiency virus (HIV)-1 subtype C.","authors":"Xingguang Li, Sana Tamim, Nídia S Trovão","doi":"10.1099/jmm.0.001827","DOIUrl":"10.1099/jmm.0.001827","url":null,"abstract":"<p><p><b>Introduction.</b> Human immunodeficiency virus (HIV)-1 subtype C is the most prevalent globally and is thought to have originated in non-human primates in the Democratic Republic of Congo.<b>Hypothesis/Gap Statement.</b> Although the global dominance of HIV-1 subtype C is well established, a thorough understanding of its evolutionary history and transmission dynamics across various risk populations remains elusive. The current knowledge is insufficient to fully capture the global diversification and dissemination of this subtype.<b>Aim.</b> We for the first time sought to investigate the global evolutionary history and spatiotemporal dynamics of HIV-1 subtype C using a selection of maximum-likelihood-based phylodynamic approaches on a total of 1210 near full-length genomic sequences sampled from 32 countries, collected in 4 continents, with sampling dates between 1986-2019 among various risk groups were analysed.<b>Methodology.</b> We subsampled the HIV-1 subtype C genomic datasets based on continent and risk group traits, and performed nucleotide substitution model selection analysis, maximum likelihood (ML) phylogenetic reconstruction, phylogenetic tree topology similarity analysis, temporal signal analysis and traced the timings of viral spread both geographically and by risk group.<b>Results.</b> Based on the phylodynamic analyses of four datasets (full1210, locrisk626, loc562 and risk393), we inferred the time to the most recent common ancestor (TMRCA) in the 1930s and an evolutionary rate of 0.0023 substitutions per site per year. The total number of introduction events of HIV-1 subtype C between continents and between risk groups is estimated to be 71 and 115, respectively. The largest number of introductions occurred from Africa to Europe (<i>n</i>=32), from not-recorded to heterosexual (<i>n</i>=40) and from heterosexual to not-recorded (<i>n</i>=51) risk groups.<b>Conclusion.</b> Our results emphasize that HIV subtype C has mainly spread from Africa to Europe, likely through heterosexual transmission.</p>","PeriodicalId":94093,"journal":{"name":"Journal of medical microbiology","volume":"73 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of medical microbiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1